Pfizer closes in on $7.3 billion takeover of anti-obesity drugmaker Metsera, FT reports
PositiveFinancial Markets

Pfizer is reportedly nearing a $7.3 billion acquisition of Metsera, a company specializing in anti-obesity drugs. This move highlights Pfizer's commitment to expanding its portfolio in the growing market for weight management solutions, which is increasingly important as obesity rates rise globally. The acquisition could enhance Pfizer's capabilities in developing innovative treatments, potentially benefiting millions of people struggling with obesity.
— Curated by the World Pulse Now AI Editorial System